Trial Profile
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open, Parallel-group Trial
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2014
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Renal impairment
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 10 Jul 2014 New trial record